183 related articles for article (PubMed ID: 8615503)
21. Reduction of centrally-stimulated gastric acid secretion by tizanidine, a new imidazoline derivative, in anesthetized rats.
Maeda-Hagiwara M; Watanabe H; Kanaoka R; Watanabe K
Arch Int Pharmacodyn Ther; 1985 Oct; 277(2):321-7. PubMed ID: 3933446
[TBL] [Abstract][Full Text] [Related]
22. Tizanidine (DS103-282), a centrally acting muscle relaxant, selectively depresses excitation of feline dorsal horn neurones to noxious peripheral stimuli by an action at alpha 2-adrenoceptors.
Davies J; Johnston SE; Hill DR; Quinlan JE
Neurosci Lett; 1984 Jul; 48(2):197-202. PubMed ID: 6090998
[TBL] [Abstract][Full Text] [Related]
23. [Tizanidine for preanesthetic medication].
Takenaka M; Iida H; Kasamatsu M; Katoh H; Tashiro T; Dohi S
Masui; 1996 Aug; 45(8):971-5. PubMed ID: 8818094
[TBL] [Abstract][Full Text] [Related]
24. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers.
Shah J; Wesnes KA; Kovelesky RA; Henney HR
Clin Ther; 2006 Sep; 28(9):1308-17. PubMed ID: 17062304
[TBL] [Abstract][Full Text] [Related]
25. Alpha-1-adrenergic receptor agonist activity of clinical alpha-adrenergic receptor agonists interferes with alpha-2-mediated analgesia.
Gil DW; Cheevers CV; Kedzie KM; Manlapaz CA; Rao S; Tang E; Donello JE
Anesthesiology; 2009 Feb; 110(2):401-7. PubMed ID: 19194166
[TBL] [Abstract][Full Text] [Related]
26. [Influence of a muscle relaxant, tizanidine, on gastric acid secretion and gastric ulcer in rats].
Watanabe K; Watanabe H; Maeda-Hagiwara M; Kanaoka R
Nihon Yakurigaku Zasshi; 1983 Oct; 82(4):237-45. PubMed ID: 6662417
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
Nance PW; Bugaresti J; Shellenberger K; Sheremata W; Martinez-Arizala A
Neurology; 1994 Nov; 44(11 Suppl 9):S44-51; discussion S51-2. PubMed ID: 7970010
[TBL] [Abstract][Full Text] [Related]
28. The effect of tizanidine on maximal electroshock seizures (MES) in mice.
Denizbaşi A; Berkman K; Ozyazgan S; Eşkazan E
Gen Pharmacol; 1999 Apr; 32(4):513-6. PubMed ID: 10323494
[TBL] [Abstract][Full Text] [Related]
29. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis.
Nance PW; Sheremata WA; Lynch SG; Vollmer T; Hudson S; Francis GS; O'Connor P; Cohen JA; Schapiro RT; Whitham R; Mass MK; Lindsey JW; Shellenberger K
Arch Neurol; 1997 Jun; 54(6):731-6. PubMed ID: 9193208
[TBL] [Abstract][Full Text] [Related]
30. Assessment of MK-467, a peripheral alpha 2-adrenergic receptor antagonist, with intravenous clonidine.
Warren JB; Dollery CT; Sciberras D; Goldberg MR
Clin Pharmacol Ther; 1991 Jul; 50(1):71-7. PubMed ID: 1677320
[TBL] [Abstract][Full Text] [Related]
31. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury.
Kamen L; Henney HR; Runyan JD
Curr Med Res Opin; 2008 Feb; 24(2):425-39. PubMed ID: 18167175
[TBL] [Abstract][Full Text] [Related]
32. Antagonism of the effects of clonidine by the alpha 2-adrenoceptor antagonist, fluparoxan.
Johnson MA; Blackwell CP; Smith J
Br J Clin Pharmacol; 1995 May; 39(5):477-83. PubMed ID: 7669482
[TBL] [Abstract][Full Text] [Related]
33. Influence of clonidine and a new related imidazoline derivative (tizanidine) on rat gastric mucosa.
Maeda-Hagiwara M; Watanabe H; Kanaoka R; Watanabe K
Pharmacology; 1986; 32(2):109-13. PubMed ID: 3952131
[TBL] [Abstract][Full Text] [Related]
34. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
Smolenski C; Muff S; Smolenski-Kautz S
Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
[TBL] [Abstract][Full Text] [Related]
35. Dose-response profiles of plasma growth hormone and vasopressin after clonidine challenge in man.
Brown GM; Mazurek M; Allen D; Szechtman B; Cleghorn JM
Psychiatry Res; 1990 Mar; 31(3):311-20. PubMed ID: 2333361
[TBL] [Abstract][Full Text] [Related]
36. Tizanidine for spasticity.
Med Lett Drugs Ther; 1997 Jul; 39(1004):62-3. PubMed ID: 9217694
[No Abstract] [Full Text] [Related]
37. Assessment of MK-912, an alpha 2-adrenoceptor antagonist, with use of intravenous clonidine.
Warren JB; Dollery CT; Fuller RW; Williams VC; Gertz BJ
Clin Pharmacol Ther; 1989 Jul; 46(1):103-9. PubMed ID: 2568210
[TBL] [Abstract][Full Text] [Related]
38. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
[TBL] [Abstract][Full Text] [Related]
39. Double-blind comparison of the hypotensive, sedative and salivary flow effects of lofexidine and clonidine in normal subjects.
Dollery CT; Reid JL
Arzneimittelforschung; 1982; 32(8a):984-7. PubMed ID: 6890374
[TBL] [Abstract][Full Text] [Related]
40. Effects of tizanidine in healthy volunteers: double-blind study compared with diazepam and a placebo.
Yanagita T; Yamamura H; Igarashi S
Int J Clin Pharmacol Res; 1988; 8(2):75-94. PubMed ID: 3378856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
